<?xml version="1.0" encoding="UTF-8"?>
<p id="Par102">In one clinical trial, 10 Chinese patients with severe cases of COVID-19 received convalescent plasma treatment after approximately 16 days of contraction [
 <xref ref-type="bibr" rid="CR102">102</xref>]. 200-mL convalescent plasma was transfused into each patient. Patients were able to tolerate this level of dosage without displaying any symptoms [
 <xref ref-type="bibr" rid="CR102">102</xref>]. Clinical symptoms significantly improved in all patients 3 days after receiving treatment followed by no traces of SARS-CoV-2 after one week. Improvement in pulmonary functions, such as oxygen saturation and lymphocyte counts, due to antibodies obtained from the treatment highlight decreased inflammation and hyperactivity of the immune system [
 <xref ref-type="bibr" rid="CR102">102</xref>]. In another clinical study in South Korea, two patients received convalescent plasma treatment. Similar to the previously described study, both patients were diagnosed with severe pneumonia and acute respiratory distress syndrome [
 <xref ref-type="bibr" rid="CR101">101</xref>]. Both patients received a total of 500Â mL dose of convalescent plasma, which was administered twice in 12-hour intervals. Patients received treatment at different times: one receiving 22 days after onset of symptoms and the other after 7 days [
 <xref ref-type="bibr" rid="CR101">101</xref>]. No adverse effects of the transfusion were present in either patient. Both patients demonstrated a significant recovery in respiratory functions and levels of lymphocytes increased almost immediately after plasma therapy [
 <xref ref-type="bibr" rid="CR101">101</xref>].
</p>
